Pharma Mar, S.A.

BME:PHM Stock Report

Market Cap: €1.2b

Pharma Mar Past Earnings Performance

Past criteria checks 4/6

Pharma Mar's earnings have been declining at an average annual rate of -44.4%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been declining at an average rate of 8.1% per year. Pharma Mar's return on equity is 17.2%, and it has net margins of 19%.

Key information

-44.42%

Earnings growth rate

-45.41%

EPS growth rate

Biotechs Industry Growth-7.17%
Revenue growth rate-8.09%
Return on equity17.22%
Net Margin18.97%
Last Earnings Update30 Sep 2025

Recent past performance updates

There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings

Nov 07
There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings

Recent updates

There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings

Nov 07
There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings

Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Nov 02
Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Is Pharma Mar (BME:PHM) A Risky Investment?

Oct 29
Is Pharma Mar (BME:PHM) A Risky Investment?

Risks To Shareholder Returns Are Elevated At These Prices For Pharma Mar, S.A. (BME:PHM)

Aug 03
Risks To Shareholder Returns Are Elevated At These Prices For Pharma Mar, S.A. (BME:PHM)

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80

Jun 16
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80

Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80

May 23
Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80
User avatar

ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe

Successful approval of ZEPZELCA in Europe and new markets could significantly boost PharmaMar’s future revenues, leveraging positive trial results.

We Think Shareholders Should Be Aware Of Some Factors Beyond Pharma Mar's (BME:PHM) Profit

Mar 06
We Think Shareholders Should Be Aware Of Some Factors Beyond Pharma Mar's (BME:PHM) Profit

There's Reason For Concern Over Pharma Mar, S.A.'s (BME:PHM) Massive 27% Price Jump

Feb 13
There's Reason For Concern Over Pharma Mar, S.A.'s (BME:PHM) Massive 27% Price Jump

Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Oct 16
Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Jul 28
Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Jun 01
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

May 28
Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 03
Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Jan 25
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Apr 28
Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Mar 08
We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Mar 05
Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Feb 09
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

Oct 27
We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Sep 27
An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Jul 15
Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

May 04
Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

Apr 11
Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Mar 16
There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Revenue & Expenses Breakdown

How Pharma Mar makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BME:PHM Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 25179345597
30 Jun 251894252100
31 Mar 25176205098
31 Dec 241752647104
30 Sep 24167145105
30 Jun 24159-251104
31 Mar 24162243105
31 Dec 2315814299
30 Sep 23168144095
30 Jun 23175214390
31 Mar 23177294285
31 Dec 22196494383
30 Sep 22235794885
30 Jun 22233854284
31 Mar 22232914176
31 Dec 21230934072
30 Sep 21188633461
30 Jun 21200673558
31 Mar 21222913556
31 Dec 202701373654
30 Sep 202461473748
30 Jun 202141243847
31 Mar 20166723948
31 Dec 1986-93851
30 Sep 19136-275858
30 Jun 1984-373861
31 Mar 19154-245969
31 Dec 18109-173974
30 Sep 18189-166680
30 Jun 18128-2044119
31 Mar 18179-266579
31 Dec 17159-285879
30 Sep 17182-226777
30 Jun 17186-187478
31 Mar 17184-196778
31 Dec 16181-246878
30 Sep 16187-186875
30 Jun 16188-107160
31 Mar 16190-77066
31 Dec 1519476960
31 Dec 14175136046

Quality Earnings: PHM has high quality earnings.

Growing Profit Margin: PHM's current net profit margins (19%) are higher than last year (0.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PHM's earnings have declined by 44.4% per year over the past 5 years.

Accelerating Growth: PHM's earnings growth over the past year (5367%) exceeds its 5-year average (-44.4% per year).

Earnings vs Industry: PHM earnings growth over the past year (5367%) exceeded the Biotechs industry 101.1%.

Return on Equity

High ROE: PHM's Return on Equity (17.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/12 18:24
End of Day Share Price 2025/11/12 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharma Mar, S.A. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Guilherme SampaioBanco BPI, S.A.
Patricia CifuentesBestinver Sociedad De Valores, S.A
Keay NakaeChardan Capital Markets, LLC